LOVENOX

LOE Approaching

enoxaparin sodium

NDAINTRAVENOUS, SUBCUTANEOUSINJECTABLEPriority Review
Approved
Mar 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
15

Mechanism of Action

properties.

Clinical Trials (5)

NCT02366871Phase 2Completed

Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy

Started Apr 2015
400 enrolled
Gynecologic CancerVenous Thromboembolism
NCT00714597Phase 3Terminated

Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility

Started Jul 2008
421 enrolled
Venous Thromboembolism
NCT00721760Phase 3Completed

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery

Started Jul 2008
1,003 enrolled
Venous Thromboembolism
NCT00916669Phase 2Withdrawn

A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)

Started Jul 2008
0
Small Cell Lung Cancer
NCT00697099Phase 3Completed

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery

Started Jun 2008
2,326 enrolled
Venous Thromboembolism